Medical News, Journals & Upcoming Events
Most Read Psychiatry Articles on JAMA Network
- Child Maltreatment Measures and Psychopathology May 1, 2024This systematic review and meta-analysis evaluates associations between childhood maltreatment and psychopathology.
- Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia May 1, 2024This randomized clinical trial evaluates the efficacy and safety of xanomeline-trospium chloride vs placebo in adults with schizophrenia.
- Cognitive Behavior Therapy vs Mindfulness in Treatment of Prolonged Grief Disorder April 24, 2024This randomized clinical trial evaluates the efficacy of grief-focused cognitive behavior therapies vs mindfulness-based cognitive therapy in individuals with prolonged grief disorder.
- Recreational Marijuana Laws and Teen Marijuana Use, 1993-2021 April 24, 2024This cross-sectional study uses data from the Youth Risk Behavior surveys to assess the association of state-level recreational marijuana laws and youth marijuana use.
- Adolescents Who Do Not Endorse Risk via the Patient Health Questionnaire Before Self-Harm or Suicide April 24, 2024This cohort study investigates the characteristics of adolescents with a history of depression who do not endorse risk on the Patient Health Questionnaire before self-harm or suicide.
JAMA Oncology Current Issue
- Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma April 1, 2024This randomized clinical trial examines if radiotherapy is noninferior to chemoradiotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
- Broken Promises April 1, 2024At first, the room teems with acquaintances Who you last saw at Thanksgiving Nearly a decade ago
- TMB in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition April 1, 2024This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.
- Pertuzumab Plus Trastuzumab Without Chemotherapy for ERBB2-Positive Metastatic Breast Cancer—Reply April 1, 2024In Reply We thank Sun and Wei for raising the important issue of survival with regard to de-escalation of chemotherapy in the presence of highly effective targeted anti-ERBB2 (formerly HER2) therapy. In their comments on our analysis, Sun and Wei conclude that between the time period of 24 to 72 months, reconstructed survival data looking […]
Upcoming Events
To receive information about upcoming events and the latest CE Activities, join our network.